About Combinati
Combinati is a Healthcare company based in Palo Alto (United States) founded in 2015 by Megan Dueck, Andrew Zayac, and Paul Hung, and was acquired by Thermo Fisher Scientific in October 2021. Integrated digital PCR platform with microfluidic consumables is developed. Combinati has raised $5.83 million across 1 funding round from investors including Thermo Fisher Scientific. Its chief executive, as recorded, is Paul Hung. The company was acqui-hired. Combinati offers products and services including QuantStudio Absolute Q Digital PCR System, TaqMan Assays, and Absolute Q Universal DNA dPCR Master Mix. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Instrument Systems. Its legal entity is Thermo Fisher Scientific Inc. Its competitors include NeuMoDx, GenMark Diagnostics and Biomeme; 3 of its 3 listed competitors have raised funding.
Company details
Combinati is developing an integrated digital PCR platform with injection-molded microfluidic consumables to advance biomedical research. It uses consumable technology that allows high-density reagent digitization on a standard format using a scalable manufacturing process. The industry-standard format allows the integration of pneumatics thermal optical and software modules into one benchtop instrument to offer a significant workflow advantage over current commercially available products. Its precision nucleic acid quantification platform would accelerate the adoption of dPCR technology in the clinic for disease prevention prognosis diagnosis as well as therapeutics efficacy monitoring.
- Headquarters Palo Alto, United States
- Founders Megan Dueck, Andrew Zayac, Paul Hung
- Stage Acquired
- SectorsHealthcare
- Website combinati.com
- Acquired by Thermo Fisher Scientific (Oct 2021)
- Legal Name Thermo Fisher Scientific Inc.
- Total Equity Funding$5.83M (USD)
in 1 rounds
- Latest Funding Round$5.83M (USD), Series A
May 2018
- Investors
- Acquired byThermo Fisher Scientific
(Oct 2021)
Products & Services of Combinati
Combinati offers a comprehensive portfolio of products and services, including QuantStudio Absolute Q Digital PCR System, TaqMan Assays, and Absolute Q Universal DNA dPCR Master Mix.
System for precise digital PCR quantification in research applications.
Probe-based kits for detecting and quantifying nucleic acids accurately.
Master mix for various digital PCR applications in gene editing.
Funding Insights of Combinati
Combinati has successfully raised a total of $5.83M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.83 million completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.83M
- Total Rounds 1
- Last Round Series A — $5.83M
- First Round $5.83M
(May 2018)
All 1 funding rounds of Combinati with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $5.83M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Combinati
Combinati has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Thermo Fisher Scientific.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Electron microscopy services and microanalysis instruments are provided. | 1956 | thermofisher.com | Waltham, United States |
Investor details for Combinati
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Combinati
1284 people are tracked at Combinati (507 in leadership, 18 in board & advisors, 759 in team).
| Name | Role | Group |
|---|---|---|
Megan Dueck | Co-Founder | Leadership |
Andrew Zayac | Co-Founder | Leadership |
Paul Hung | Co-Founder & CEO | Leadership |
Mike Shafer | SVP & President, Pharma Services | Leadership |
Nader Riad | Director, Advanced Engineering | Leadership |
Rachelle Sepich | Senoir HR Director | Leadership |
Benjamin Chong | Senior Director HR | Leadership |
Tony Farero | Director HR, Global Quality | Leadership |
David Reirden | VP, HR Productivity & Operations | Leadership |
Francis Baker | Senior Director, HR PMO & LR | Leadership |
Praveen Chauhan | Head Of Information Technology | Leadership |
James Niblock | Director, Managed Access Programs | Leadership |
Angela Thomas | Senior Director Growth & Strategy | Leadership |
Juan Semanate | Sr. Director - Operations | Leadership |
Lori Petersen | Senior HR Director | Leadership |
Jessika Fabiano | Director, Early Talent Programs | Leadership |
Stewart Han | Director, Marketing | Transplant Diagnostics | Leadership |
Sjoerd van Den Boom | Director Mechanical Sub-assemblies - Global Procurement Bij Thermo Fisher Scientific | Leadership |
Aaron Basey | Sr. Director Digital Product Management | Leadership |
Alexander Makarov | Director Global Research | Leadership |
1264 more people are available in the full profile.
Complete people profiles for Combinati
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Combinati
3 dated milestones of Combinati across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Combinati is founded.
- Funding First funding round of $5.8M.
- Exit Acquired by Thermo Fisher Scientific.
Competitors of Combinati
Combinati has 3 listed competitors in our database, 3 of them funded. They include NeuMoDx, GenMark Diagnostics and Biomeme.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| neumodx.com | 2012 | Ann Arbor, United States | $66.04M | 125 | Developer of a platform for low cost molecular testing | |
| genmarkdx.com | 1993 | San Diego, United States | $8.56M | 797 | Instruments and test panels for multiplexed molecular diagnostics are provided. | |
| biomeme.com | 2013 | Philadelphia, United States | $6.2M | 202 | Smartphone-based DNA detection platform is developed for diagnostics. |
Detailed competitors of Combinati
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Combinati (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Combinati
Complete news archive for Combinati
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Combinati
Combinati was founded in 2015 and raised its 1st funding round 3 years after it was founded.
Combinati is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Paul Hung is the CEO of Combinati, as recorded in our data. They have also founded this company.
Combinati is a funded company, having raised a total of $5.83M across 1 funding round to date. The company's 1st funding round was a Series A of $5.83M, raised on May 2018.
Combinati is developing an integrated digital PCR platform with injection-molded microfluidic consumables to advance biomedical research. It uses consumable technology that allows high-density reagent digitization on a standard format using a scalable manufacturing process. The industry-standard format allows the integration of pneumatics thermal optical and software modules into one benchtop instrument to offer a significant workflow advantage over current commercially available products. Its precision nucleic acid quantification platform would accelerate the adoption of dPCR technology in the clinic for disease prevention prognosis diagnosis as well as therapeutics efficacy monitoring.
Combinati's top competitors include GenMark Diagnostics, NeuMoDx and Biomeme.
Combinati offers QuantStudio Absolute Q Digital PCR System, TaqMan Assays, and Absolute Q Universal DNA dPCR Master Mix.
Combinati has 1 investor. Key investors include Thermo Fisher Scientific.
Combinati operates through Thermo Fisher Scientific Inc..
Yes. Combinati was acquired by Thermo Fisher Scientific in October 2021.